289
1. Akat, A., Karaöz, E. A systematic review of cell therapy modalities and outcomes in cerebral palsy. Mol Cell Biochem 480, 891–922 (2025). https://doi.org/10.1007/s11010-024-05072-3
2. Amanat M, Majmaa A, Zarrabi M, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther 2021;12:439. 10.1186/s13287-021-02513-4
3. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11:268–277. doi: 10.1038/nrc3034.
4. Bennet, L., Tan, S., Van den Heuij, L., Derrick, M., Groenendaal, F., van Bel, F., et al. (2012). Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Ann. Neurol. 71 (5), 589–600. doi:10.1002/ana.22670
5. Blair E, Langdon K, McIntyre S, Lawrence D, Watson L. Survival and mortality in cerebral palsy: observations to the sixth decade from a data linkage study of a total population register and National Death Index. BMC Neurol. 2019; 19:111.
6. Boyalı O., Kabatas S., Erdinç Civelek E, et al.Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World J Clin Cases 2024 March 26; 12(9): 1585-1596. DOI: 10.12998/wjcc. v12.i9.1585
7. Carroll JE, Mays RW. Update on stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2011;11:463–471. doi: 10.1517/14712598.2011.557060.
8. Colver, A., Fairhurst, C., and Pharoah, P. O. (2014). Cerebral palsy. Lancet 383 (9924), 1240–1249. doi:10.1016/s0140-6736(13)61835-8
9. Cumpston, M., Li, T., Page, M. J., Chandler, J., , et al. (2019). Updated guidance for trusted systematic reviews: A new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst. Rev. 10, Ed000142. doi:10.1002/14651858.ed000142
10. , , et al. Stem cell treatment and cerebral palsy: Systemic review and meta-analysis. World J. Stem Cells 2019; 11: 891–903.
11. Felfly H, Haddad GG. Hematopoietic stem cells: Potential new applications for translational medicine. J Stem Cells. 2014;9:163–197.
12. Forraz N, McGuckin CP. The umbilical cord: A rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60–69. doi: 10.1111/j.1365-2184.2010.00729.x.
13. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Front Pharmacol. 2017;8:628. doi: 10.3389/fphar.2017.00628.
14. Gluckman E. Milestones in umbilical cord blood transplantation. Blood Rev 2011;25:255-9. 10.1016/j.blre.2011.06.003
15. Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther 2020;11:43. 10.1186/s13287-019-1545
16. Hawley RG, Ramezani A, Hawley TS. Hematopoietic stem cells. Methods Enzymol. 2006;419:149–179. doi: 10.1016/S0076-6879(06)19007-2.
17. Hayles E, Jones A, Harvey D, Plummer D, Ruston S. Delivering healthcare services to children with cerebral palsy and their families: a narrative review. Health Soc Care Community. 2015; 23:242---51.
18. Lv Z. , Li Y., Wang Y. et al.,Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial. Lv et al. Stem Cell Research & Therapy (2023) 14:23 https://doi.org/10.1186/s13287-022-03234-y
19. M.J.P. Cantero, E.E.M. Medinilla, A.C. Martínez et al. Comprehensive approach to children with cerebral palsy. anales-de-pediatria-english-volume 95 ,İssue 4,October 2021, Pages 276.e1-276. https://doi.org/10.1016/j.anpede.2021.07.002
20. Maroof, A. M., Keros, S., Tyson, J. A., , et al. (2013). Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell stem Cell 12 (5), 559–572. doi:10.1016/j.stem.2013.04.008
21. , , . Consensus research priorities for cerebral palsy: A Delphi survey of consumers, researchers, and clinicians. Dev. Med. Child Neurol. 2010; 52: 270–5.
22. Mukai T, Tojo A, Nagamura-Inoue T. Mesenchymal stromal cells as a potential therapeutic for neurological disorders. Regen Ther. 2018;9:32–37. doi: 10.1016/j.reth.2018.08.001.
23. Murohara T. Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. Trends Cardiovasc Med. 2001;11:303–307. doi: 10.1016/s1050-1738(01)00128-1.
24. Nassim H. Abi Chahine , Tarek W . et al. Treatment of Cerebral Palsy with Stem Cells: A Report of 17 Cases. International Journal of Stem Cells Vol. 9, No. 1, 2016. https://doi.org/10.15283/ijsc.2016.9.1.90
25. Novak I, Walker K, Hunt RW, Wallace EM, Fahey M, Badawi N. Concise review: Stem cells interventions for people with cerebral palsy: Systematic review with meta-analysis. Stem Cells Transl. Med. 2016; 5: 1014–25.
26. Oskoui M, Coutinho F, Dykeman J, et al. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2013;55(6):509–
27. Paton MCB, Finch-Edmondson M, Fahey MC, London J, Badawi N, Novak I. Fifteen years of human research using stem cells for cerebral palsy: A review of the research landscape. J Paediatr Child Health. 2021;57(2):295–296. https://doi.org/10.1111/jpc.1532914.
28. Porada CD, Atala AJ, Almeida-Porada G. The hematopoietic system in the context of regenerative medicine. Methods. 2016;99:44–61. doi: 10.1016/j.ymeth.2015.08.015.
29. Qu J., Zhou L.,Zhang H. Et al. Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis Front. Bioeng. Biotechnol., 14 December 2022
30. Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral Palsy: Current Opinions on Definition, Epidemiology, Risk Factors, Classification and Treatment Options. Neuropsychiatr Dis Treat. 2020; 16:1505–1518. doi: 10.2147/NDT.S235165.
31. Sayed . R. E. Shankar K. M. Mankame A. R. Innovations in cell therapy in pediatric diseases: a narrative review. Transl Pediatr. 2023 Jun 30;12(6):1239-1257. doi: 10.21037/tp-23-92
32. Sec. Tissue Engineering and Regenerative Medicine
33. Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P, Jacob VC. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21( Suppl 1):S79–S90. doi: 10.3727/096368912X633798.
34. Siniscalco, D., Bradstreet, J. J., Sych, N.et al. Perspectives on the use of stem cells for autism treatment. Stem cells Int. 2013, 1–7. doi:10.1155/2013/262438
35. Slack JMW. What is a stem cell? Wiley Interdiscip Rev Dev Biol. 2018:e323. doi: 10.1002/wdev.323. [
36. Sohni, A., and Verfaillie, C. M. (2013). Mesenchymal stem cells migration homing and tracking. Stem cells Int. 2013, 1–8. doi:10.1155/2013/130763
37. , , et al. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010; 50: 1980–7.
38. Sun JM, Kurtzberg J. Stem cell therapies in cerebral palsy and autism spectrum disorder. Dev Med Child Neurol. 2021;63(5):503–10.
39. Takasaki Y, et al. Estimation of the distribution of intravenously injected adipose tissue-derived stem cells labeled with quantum dots in mice organs through the determination of their metallic components by ICPMS. Anal Chem. 2011;83(21):8252–8.
40. Tanaka N, Kamei N, Nakamae T, Yamamoto R, Ishikawa M, Fujiwara H, Miyoshi H, Asahara T, Ochi M, Kudo Y. CD133+ cells from human umbilical cord blood reduce cortical damage and promote axonal growth in neonatal rat organ co-cultures exposed to hypoxia. Int J Dev Neurosci. 2010;28:581–587. doi: 10.1016/j.ijdevneu.2010.07.232.
41. Volume 10 - 2022 | https://doi.org/10.3389/fbioe.2022.1006845
42. Zhong-Yue L., Ying L., Jing L.Progress in clinical trials of stem cell therapy for cerebral palsy. Neural Regeneration Research 16(7): p 1377-1382, July 2021. | DOI: 10.4103/1673-5374. 300979